Developer docs
API playgroundTry for free, no card

Search company profiles

Biora Therapeutics

Full company profile

uuid0004tqi

Namestring
Biora Therapeutics
Legal namestring
BT Bidco, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Biora Therapeutics is a clinical-stage biotechnology company developing two proprietary smart-pill drug delivery platforms. The BioJet platform is a swallowable 00-size capsule that uses patented liquid jet injection technology to deliver large molecules (proteins, peptides, antibodies, nucleic acids) directly into the small intestine for systemic uptake, achieving greater than 25% mean oral bioavailability in large animal models versus less than 1% for oral tablet alternatives. The NaviCap platform is an ingestible smart capsule equipped with proprietary GITrac optical autolocation technology that autonomously identifies the colon and releases liquid drug formulations directly to colonic mucosa for the treatment of inflammatory bowel disease. The company's internal pipeline includes BT-600 (NaviCap + tofacitinib, Phase 1 complete), BT-001 (NaviCap + adalimumab variant, preclinical), and PGN-OB1 (BioJet + adalimumab variant, preclinical).

Biora generates revenue through platform licensing and co-development agreements with pharmaceutical partners seeking to convert injectable biologics into oral dosage forms, with named collaborators including AstraZeneca and Ionis Pharmaceuticals alongside multiple undisclosed large pharma partners. The company also advances its own pipeline programs through clinical development to generate proof-of-concept data that supports broader partnership conversion and future out-licensing.

The company was originally incorporated as Progenity, Inc., completed an IPO in June 2020, and underwent a court-supervised restructuring that concluded on March 31, 2025, when it emerged as a privately held entity under BT Bidco, Inc. with ownership transferred to lender groups including Davidson Kempner Capital Management LP, Context Capital Management LLC, and Highbridge Capital Management LLC. The company is headquartered in San Diego, California and employs 51-100 people. All products are investigational and not commercially available.

Short descriptiontext

Biora Therapeutics is a clinical-stage biotech developing two proprietary smart-pill platforms — BioJet for needle-free oral delivery of large molecules and NaviCap for targeted colon drug delivery — serving pharmaceutical partners through licensing, co-development, and internal pipeline programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral biologic delivery, smart pill platforms, targeted GI therapeutics, drug-device combinations, ingestible drug delivery
Industry4 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAHAIAB
Auto-Injectors (Disposable & Reusable)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oral Drug Delivery Platforms
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Platform Licensing and Co-development Agreements
TypeLicensing Royalties
Description

Biora generates revenue through licensing its drug delivery platforms (BioJet, NaviCap) to pharmaceutical companies. Pharma partners pay for access to the technology to enable oral delivery of their proprietary molecules. Collaborations may include upfront payments, development milestones, and royalties on approved products.

bioratherapeutics.com
2Internal Drug Pipeline Development
TypeLicensing Royalties
Description

Biora develops proprietary drug/device combination products (BT-600, BT-001) through clinical development, with the intent to out-license or partner these programs at key inflection points. Revenue would come from upfront payments, milestone payments, and royalties upon partner commercialization.

bioratherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NaviCap
Description

Targeted therapeutic delivery platform using an ingestible smart capsule designed for delivery of therapeutics to the large intestine to improve the treatment of inflammatory bowel disease (IBD), with an initial focus on ulcerative colitis.

+2 more records
Core offering1 text field

Biora Therapeutics develops and licenses two proprietary smart-pill drug/device combination platforms: the BioJet swallowable autoinjector that delivers large molecules (proteins, peptides, antibodies, nucleic acids) into the small intestine via liquid jet injection, and the NaviCap ingestible capsule that uses GITrac autolocation technology to deliver drug formulations directly to the colon for localized IBD treatment. The company advances internal pipeline programs (BT-600, BT-001, PGN-OB1) through clinical development and partners with large pharmaceutical companies to convert injectable biologics into oral dosage forms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • BioJet achieved >25% mean oral bioavailability for peptides and antibodies in large animal models, reaching up to 50% for antibodies (vs <1% for oral tablet semaglutide and 1–5% for permeation enhancer technologies)
+5 more records
Product overview1 text field

Biora Therapeutics develops two distinct smart-pill technology platforms for drug delivery: (1) The BioJet™ platform is a swallowable autoinjector for needle-free, oral delivery of large molecules (proteins, peptides, antibodies, nucleic acids) via liquid jet injection to the small intestine, achieving >25-50% oral bioavailability versus IV; (2) The NaviCap™ platform is a targeted therapeutic delivery system using GITrac™ autolocation technology to deliver drugs directly to the colon mucosa for localized treatment of inflammatory bowel disease. The pipeline includes BT-600 (NaviCap + tofacitinib for ulcerative colitis) which completed Phase 1, BT-001 (NaviCap + adalimumab variant), and PGN-OB1 (BioJet + adalimumab variant).

Product and service5 records
1BioJet Oral Therapeutic Delivery Platform
CategoryDrug Delivery Platform
Description

Swallowable 00-size capsule platform that uses patented liquid jet injection to deliver proteins, peptides, antibodies, and nucleic acids (>300 microliter payloads, >50 mg doses) into the small intestine for systemic uptake without needles or reformulation. Targeted at pharma partners needing to convert injectable biologics into oral dosage forms.

2NaviCap Targeted Therapeutic Delivery Platform
CategoryDrug Delivery Platform
Description

Ingestible smart capsule platform equipped with GITrac autolocation optical sensing that autonomously identifies the colon independent of pH, transit time, food intake, or disease state, and delivers liquid drug formulations directly to colonic mucosa for treatment of inflammatory bowel disease. Targeted at pharma partners developing IBD therapies.

3BT-600 (NaviCap + Tofacitinib)
CategoryPipeline Product - Ulcerative Colitis
Description

Internal pipeline drug/device combination product pairing the NaviCap targeted delivery platform with orally delivered liquid tofacitinib for treatment of ulcerative colitis; Phase 1 complete with demonstrated pan-colonic tissue delivery and lower systemic exposure than conventional oral tofacitinib.

4BT-001 (NaviCap + Adalimumab Variant)
CategoryPipeline Product - Ulcerative Colitis
Description

Internal pipeline drug/device combination of the NaviCap platform with an orally delivered anti-TNF-alpha monoclonal antibody variant for treatment of ulcerative colitis, currently in preclinical stage development.

5PGN-OB1 (BioJet + Adalimumab Variant)
CategoryPipeline Product - Inflammatory Conditions
Description

Internal pipeline combination of BioJet liquid jet delivery with an adalimumab variant for systemic oral delivery to treat inflammatory conditions, achieving up to 55% bioavailability in preclinical swine studies.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or Integration
Description

Biora collaborates with AstraZeneca on the BioJet platform for needle-free oral delivery of large molecules. The collaboration involves using BioJet's swallowable autoinjector technology to enable oral dosing of AstraZeneca pipeline molecules that are currently delivered by injection.

Strategic tierCoreTypeTechnology or Integration
Description

Biora collaborates with Ionis Pharmaceuticals on the BioJet platform for oral delivery of antisense oligonucleotides and other nucleic acid therapeutics. Ionis is leveraging BioJet's liquid jet injection technology to explore oral administration of its proprietary RNA-targeted therapeutics.

3Undisclosed Large Pharma Partners
Strategic tierCoreTypeTechnology or Integration
Description

Biora has active collaborations with multiple undisclosed large pharmaceutical companies for both the BioJet and NaviCap platforms. CEO Mohanty notes multiple pharma collaborations are progressing well, with the company advancing toward IND-readiness for its BioJet platform.

bioratherapeutics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor developing a robotic pill (RaniPill) for oral delivery of biologics including peptides, proteins, and antibodies. Both companies target the same pharma partnership opportunity to convert injectable biologics into oral dosage forms, with similar value proposition and pre-revenue clinical stage.

TypeDirect peer
Description

Developed long-acting oral drug delivery systems, including gastric-retentive capsules for sustained drug release. Directly comparable as an oral drug delivery platform company targeting pharma partnerships, though with different technical approach (gastric retention vs Biora's liquid jet injection).

TypeBroad incumbent
Description

Major pharma investing in oral peptide and biologic delivery technologies, including partnerships and internal R&D. Represents a potential partner or competitor as Novartis seeks to differentiate its biologics portfolio through oral formulations.

TypeBroad incumbent
Description

Major pharma with active oral peptide/biologics programs including GLP-1 development. Relevant as a potential partner for BioJet platform or competitive threat given established oral formulation capabilities.

TypeBroad incumbent
Description

Developed oral GLP-1 therapies (orforglipron) and has extensive biologics portfolio potentially seeking oral conversion. Competes in the oral peptide space and represents a high-value potential partner for BioJet technology.

TypeBroad incumbent
Description

Leader in GLP-1 therapies with oral semaglutide (Rybelsus) already commercialized. Represents the benchmark for oral peptide delivery and a potential partner for next-generation oral biologics using BioJet's higher bioavailability approach.

TypeBroad incumbent
Description

Specialty pharma focused on drug delivery technologies, particularly for pain and addiction therapies. Comparable business model combining drug delivery innovation with specialty pharmaceutical development.

TypeEmerging player
Description

Developed medical devices for GI-related conditions including obesity. Comparable as a small-cap medical device company focused on GI applications, though focused on neuromodulation rather than drug delivery.

TypeOthers
Description

Biora Therapeutics' predecessor company (Progenity, Inc.) which was restructured in March 2025. Included historical focus on prenatal diagnostics and GI disease diagnostics, now refocused on therapeutic delivery platforms.

TypeEmerging player
Description

Developed ingestible capsule technology (CapsoCam Plus) for GI imaging. Comparable as an ingestible smart pill technology company, though focused on diagnostic imaging rather than therapeutic delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biora Therapeutics

Oral Drug Delivery Platformsbioratherapeutics.com

Biora Therapeutics is a clinical-stage biotech developing two proprietary smart-pill platforms — BioJet for needle-free oral delivery of large molecules and NaviCap for targeted colon drug delivery — serving pharmaceutical partners through licensing, co-development, and internal pipeline programs.

What Biora Therapeutics does

Biora Therapeutics is a clinical-stage biotechnology company developing two proprietary smart-pill drug delivery platforms. The BioJet platform is a swallowable 00-size capsule that uses patented liquid jet injection technology to deliver large molecules (proteins, peptides, antibodies, nucleic acids) directly into the small intestine for systemic uptake, achieving greater than 25% mean oral bioavailability in large animal models versus less than 1% for oral tablet alternatives. The NaviCap platform is an ingestible smart capsule equipped with proprietary GITrac optical autolocation technology that autonomously identifies the colon and releases liquid drug formulations directly to colonic mucosa for the treatment of inflammatory bowel disease. The company's internal pipeline includes BT-600 (NaviCap + tofacitinib, Phase 1 complete), BT-001 (NaviCap + adalimumab variant, preclinical), and PGN-OB1 (BioJet + adalimumab variant, preclinical).

Biora generates revenue through platform licensing and co-development agreements with pharmaceutical partners seeking to convert injectable biologics into oral dosage forms, with named collaborators including AstraZeneca and Ionis Pharmaceuticals alongside multiple undisclosed large pharma partners. The company also advances its own pipeline programs through clinical development to generate proof-of-concept data that supports broader partnership conversion and future out-licensing.

The company was originally incorporated as Progenity, Inc., completed an IPO in June 2020, and underwent a court-supervised restructuring that concluded on March 31, 2025, when it emerged as a privately held entity under BT Bidco, Inc. with ownership transferred to lender groups including Davidson Kempner Capital Management LP, Context Capital Management LLC, and Highbridge Capital Management LLC. The company is headquartered in San Diego, California and employs 51-100 people. All products are investigational and not commercially available.

Biora Therapeutics firmographics

Firmographics
Name
Biora Therapeutics
Legal name
BT Bidco, Inc.
Website
https://bioratherapeutics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Biora Therapeutics is a clinical-stage biotech developing two proprietary smart-pill platforms — BioJet for needle-free oral delivery of large molecules and NaviCap for targeted colon drug delivery — serving pharmaceutical partners through licensing, co-development, and internal pipeline programs.
Ownership category
akta.pro rank

Biora Therapeutics industry classification

Industry
Product category
Oral Drug Delivery Platforms
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAHAIAB
Auto-Injectors (Disposable & Reusable)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Oral biologic delivery
  • Smart pill platforms
  • Targeted GI therapeutics
  • Drug-device combinations
  • Ingestible drug delivery

Where Biora Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Biora Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Platform Licensing and Co-development Agreements: Biora generates revenue through licensing its drug delivery platforms (BioJet, NaviCap) to pharmaceutical companies. Pharma partners pay for access to the technology to enable oral delivery of their proprietary molecules. Collaborations may include upfront payments, development milestones, and royalties on approved products.
  2. Internal Drug Pipeline Development: Biora develops proprietary drug/device combination products (BT-600, BT-001) through clinical development, with the intent to out-license or partner these programs at key inflection points. Revenue would come from upfront payments, milestone payments, and royalties upon partner commercialization.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Biora Therapeutics product offering

Product offering

Core offering

Biora Therapeutics develops and licenses two proprietary smart-pill drug/device combination platforms: the BioJet swallowable autoinjector that delivers large molecules (proteins, peptides, antibodies, nucleic acids) into the small intestine via liquid jet injection, and the NaviCap ingestible capsule that uses GITrac autolocation technology to deliver drug formulations directly to the colon for localized IBD treatment. The company advances internal pipeline programs (BT-600, BT-001, PGN-OB1) through clinical development and partners with large pharmaceutical companies to convert injectable biologics into oral dosage forms.

Product overview

Biora Therapeutics develops two distinct smart-pill technology platforms for drug delivery: (1) The BioJet™ platform is a swallowable autoinjector for needle-free, oral delivery of large molecules (proteins, peptides, antibodies, nucleic acids) via liquid jet injection to the small intestine, achieving >25-50% oral bioavailability versus IV; (2) The NaviCap™ platform is a targeted therapeutic delivery system using GITrac™ autolocation technology to deliver drugs directly to the colon mucosa for localized treatment of inflammatory bowel disease. The pipeline includes BT-600 (NaviCap + tofacitinib for ulcerative colitis) which completed Phase 1, BT-001 (NaviCap + adalimumab variant), and PGN-OB1 (BioJet + adalimumab variant).

Differentiator

Problem solved

Functional benefit

Brands

  • NaviCap: Targeted therapeutic delivery platform using an ingestible smart capsule designed for delivery of therapeutics to the large intestine to improve the treatment of inflammatory bowel disease (IBD), with an initial focus on ulcerative colitis.
  • BioJet
  • GITrac

Products and services

  • BioJet Oral Therapeutic Delivery Platform Swallowable 00-size capsule platform that uses patented liquid jet injection to deliver proteins, peptides, antibodies, and nucleic acids (>300 microliter payloads, >50 mg doses) into the small intestine for systemic uptake without needles or reformulation. Targeted at pharma partners needing to convert injectable biologics into oral dosage forms.
  • NaviCap Targeted Therapeutic Delivery Platform Ingestible smart capsule platform equipped with GITrac autolocation optical sensing that autonomously identifies the colon independent of pH, transit time, food intake, or disease state, and delivers liquid drug formulations directly to colonic mucosa for treatment of inflammatory bowel disease. Targeted at pharma partners developing IBD therapies.
  • BT-600 (NaviCap + Tofacitinib) Internal pipeline drug/device combination product pairing the NaviCap targeted delivery platform with orally delivered liquid tofacitinib for treatment of ulcerative colitis; Phase 1 complete with demonstrated pan-colonic tissue delivery and lower systemic exposure than conventional oral tofacitinib.
  • BT-001 (NaviCap + Adalimumab Variant) Internal pipeline drug/device combination of the NaviCap platform with an orally delivered anti-TNF-alpha monoclonal antibody variant for treatment of ulcerative colitis, currently in preclinical stage development.
  • PGN-OB1 (BioJet + Adalimumab Variant) Internal pipeline combination of BioJet liquid jet delivery with an adalimumab variant for systemic oral delivery to treat inflammatory conditions, achieving up to 55% bioavailability in preclinical swine studies.

Quantifiable outcome

  • BioJet achieved >25% mean oral bioavailability for peptides and antibodies in large animal models, reaching up to 50% for antibodies (vs <1% for oral tablet semaglutide and 1–5% for permeation enhancer technologies)
  • +5 more outcomes

Companies that use Biora Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Biora Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Biora Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • AstraZenecacoreTechnology or IntegrationBiora collaborates with AstraZeneca on the BioJet platform for needle-free oral delivery of large molecules. The collaboration involves using BioJet's swallowable autoinjector technology to enable oral dosing of AstraZeneca pipeline molecules that are currently delivered by injection.
  • Ionis PharmaceuticalscoreTechnology or IntegrationBiora collaborates with Ionis Pharmaceuticals on the BioJet platform for oral delivery of antisense oligonucleotides and other nucleic acid therapeutics. Ionis is leveraging BioJet's liquid jet injection technology to explore oral administration of its proprietary RNA-targeted therapeutics.
  • Undisclosed Large Pharma PartnerscoreTechnology or IntegrationBiora has active collaborations with multiple undisclosed large pharmaceutical companies for both the BioJet and NaviCap platforms. CEO Mohanty notes multiple pharma collaborations are progressing well, with the company advancing toward IND-readiness for its BioJet platform.

Scale indicators10 records

Recent moves7 records

Expansion highlights4 records

Biora Therapeutics competitors and assessment

Company assessment

Direct peers

  • Rani Therapeutics: Direct competitor developing a robotic pill (RaniPill) for oral delivery of biologics including peptides, proteins, and antibodies. Both companies target the same pharma partnership opportunity to convert injectable biologics into oral dosage forms, with similar value proposition and pre-revenue clinical stage.
  • Lyndra Therapeutics: Developed long-acting oral drug delivery systems, including gastric-retentive capsules for sustained drug release. Directly comparable as an oral drug delivery platform company targeting pharma partnerships, though with different technical approach (gastric retention vs Biora's liquid jet injection).

Broad incumbents

  • Novartis (oral biologics initiative): Major pharma investing in oral peptide and biologic delivery technologies, including partnerships and internal R&D. Represents a potential partner or competitor as Novartis seeks to differentiate its biologics portfolio through oral formulations.
  • Pfizer (oral biologics initiative): Major pharma with active oral peptide/biologics programs including GLP-1 development. Relevant as a potential partner for BioJet platform or competitive threat given established oral formulation capabilities.
  • Eli Lilly: Developed oral GLP-1 therapies (orforglipron) and has extensive biologics portfolio potentially seeking oral conversion. Competes in the oral peptide space and represents a high-value potential partner for BioJet technology.
  • Novo Nordisk: Leader in GLP-1 therapies with oral semaglutide (Rybelsus) already commercialized. Represents the benchmark for oral peptide delivery and a potential partner for next-generation oral biologics using BioJet's higher bioavailability approach.
  • BioDelivery Sciences International: Specialty pharma focused on drug delivery technologies, particularly for pain and addiction therapies. Comparable business model combining drug delivery innovation with specialty pharmaceutical development.

Emerging players

  • EnteroMedics (now ReShape Lifesciences): Developed medical devices for GI-related conditions including obesity. Comparable as a small-cap medical device company focused on GI applications, though focused on neuromodulation rather than drug delivery.
  • CapsoVision: Developed ingestible capsule technology (CapsoCam Plus) for GI imaging. Comparable as an ingestible smart pill technology company, though focused on diagnostic imaging rather than therapeutic delivery.

Others

  • Progenity (predecessor entity): Biora Therapeutics' predecessor company (Progenity, Inc.) which was restructured in March 2025. Included historical focus on prenatal diagnostics and GI disease diagnostics, now refocused on therapeutic delivery platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Biora Therapeutics social profiles

Digital presence

Biora Therapeutics compliance and trust

Trust signal

Compliance3 records

Biora Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biora Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Biora Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biora Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biora Therapeutics

What does Biora Therapeutics do?

Biora Therapeutics develops and licenses two proprietary smart-pill drug/device combination platforms: the BioJet swallowable autoinjector that delivers large molecules (proteins, peptides, antibodies, nucleic acids) into the small intestine via liquid jet injection, and the NaviCap ingestible capsule that uses GITrac autolocation technology to deliver drug formulations directly to the colon for localized IBD treatment. The company advances internal pipeline programs (BT-600, BT-001, PGN-OB1) through clinical development and partners with large pharmaceutical companies to convert injectable biologics into oral dosage forms.

Is Biora Therapeutics a public or private company?

Biora Therapeutics is a private company. It is classified as private equity controlled and is currently operating.

When was Biora Therapeutics founded?

Biora Therapeutics was founded in 2020. It employs 11 to 50 people.

Where is Biora Therapeutics based?

Biora Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Biora Therapeutics make money?

Two revenue lines are on record. Platform Licensing and Co-development Agreements are the primary driver. The others are internal Drug Pipeline Development.

Who are Biora Therapeutics's main competitors?

Direct peers on record are Rani Therapeutics and Lyndra Therapeutics. Broad incumbents are Novartis (oral biologics initiative), Pfizer (oral biologics initiative), Eli Lilly, Novo Nordisk and BioDelivery Sciences International. Emerging players are EnteroMedics (now ReShape Lifesciences) and CapsoVision. Progenity (predecessor entity) is listed as an others.

Does Biora Therapeutics have an API?

No public API is recorded for Biora Therapeutics.

What industry is Biora Therapeutics in?

Biora Therapeutics's product category is Oral Drug Delivery Platforms. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAHAIAB, Auto-Injectors (Disposable & Reusable). Its NAICS code is 541714 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceBiora Therapeutics to Initiate First Human Trial of BioJet™ Oral Biologic Delivery CapsuleBiora Therapeutics announced plans to initiate a first-in-human trial of its BioJet oral capsule for adalimumab by end of 2026. The trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers, with topline data expected early 2027. The company aims to support a 2027 regulatory filing for clinical development.GlobeNewswireBiora Therapeutics Advances BioJet™ Swallowable AutoinjectorBiora Therapeutics announced progress with its BioJet swallowable autoinjector, reporting over 25% oral bioavailability in swine and non-human primates. The platform delivered peptides and antibodies with bioavailability up to 50% versus IV, and has dosed over 600 devices in large animal studies with no safety issues. The company expects to advance the device toward IND-readiness and is progressing multiple collaborations.BioSpaceBiora Therapeutics Advances BioJet™ Swallowable AutoinjectorBiora Therapeutics announced significant progress with its BioJet™ swallowable autoinjector platform, achieving greater than 25% mean oral bioavailability for peptides and antibodies in large animal models, with levels reaching up to 50% for antibodies. The biotech company, which recently emerged from restructuring as a privately held entity, reports no safety-related issues across more than 600 device doses in preclinical studies. The company is progressing multiple pharma collaborations and advancing toward IND-readiness, seeing opportunities for pipeline molecules and established biomolecule brands to improve patient convenience through needle-free oral delivery.PR NewswireGlancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of Progenity, Inc. n/k/a Biora Therapeutics, Inc. common stock - BIORQGlancy Prongay & Murray LLP announced that a United States District Court approved a proposed $1,000,000 settlement in the securities class action litigation against Progenity, Inc. (n/k/a Biora Therapeutics, Inc.). The settlement resolves claims on behalf of purchasers who acquired common stock between June 18, 2020, and December 2, 2020. A fairness hearing is scheduled for February 23, 2026, to determine if the settlement terms are adequate.GlobeNewswireBiora Therapeutics Successfully Completes Restructuring ProcessBiora Therapeutics completed its court-supervised restructuring, emerging as a privately held company with deleveraged debt and new financing. Ownership transferred to lenders including Davidson Kempner, Context Capital, and Highbridge Capital. The company will now accelerate development of its BioJet platform, which delivers over 300 microliters orally.BenzingaWhy Biora Therapeutics (BIOR) Stock Is Down 45%Biora Therapeutics Inc announced it will be delisted from the Nasdaq exchange after the Nasdaq Hearings Panel determined the company failed to meet market value requirements under Listing Rule 5550(b). The company's shares plummeted 45% to 74 cents during trading, with Nasdaq scheduled to file a Form 25 to formalize the delisting after appeal periods expire. Trading on Nasdaq will cease at market open on December 11, and Biora expects its shares to transition immediately to the OTC Pink Current Information tier.InsideprecisionmedicineA Pill for That: Biora’s Innovative Pills Aim to Optimize Drug DeliveryBiora Therapeutics is advancing two drug delivery platforms, BioJet and NaviCap, to convert injectable biologics into oral pills for systemic and targeted treatment. The company has secured partnerships with AstraZeneca and Ionis for its BioJet platform while developing BT-600 for ulcerative colitis using its NaviCap technology. Despite promising preclinical data, Biora faces regulatory pressure from Nasdaq regarding continued listing requirements by November 2024.GlobeNewswireBiora Therapeutics Provides Corporate UpdateBiora Therapeutics reported Q2 2024 results, including $6.5 million net income and up to $16 million in funding from existing investors. Its Phase 1 trial for BT-600 met objectives, showing precise colon delivery with lower systemic exposure. The company plans to present data at the American College of Gastroenterology meeting in October and initiate a Phase 1B study toward end of 2024.YahooBiora Therapeutics Announces Funding Agreement with Existing InvestorsBiora Therapeutics has secured a $16 million multiple-draw financing facility from existing convertible note holders to serve as bridge funding. This capital is intended to support the company until it anticipates entering into a partnership with a large pharmaceutical firm, driven by positive interest in its BioJet platform and recent clinical data for NaviCap.